BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30605489)

  • 1. Increased von Willebrand factor parameters in children with febrile seizures.
    Pechmann A; Wellmann S; Stoecklin B; Krüger M; Zieger B
    PLoS One; 2019; 14(1):e0210004. PubMed ID: 30605489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copeptin as a serum biomarker of febrile seizures.
    Stöcklin B; Fouzas S; Schillinger P; Cayir S; Skendaj R; Ramser M; Weber P; Wellmann S
    PLoS One; 2015; 10(4):e0124663. PubMed ID: 25894585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired von Willebrand syndrome in paediatric patients during mechanical circulatory support.
    Kubicki R; Stiller B; Kroll J; Siepe M; Beyersdorf F; Benk C; Höhn R; Grohmann J; Fleck T; Zieger B
    Eur J Cardiothorac Surg; 2019 Jun; 55(6):1194-1201. PubMed ID: 30590475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
    Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II.
    Heilmann C; Trummer G; Beyersdorf F; Brehm K; Berchtold-Herz M; Schelling J; Geisen U; Zieger B
    Eur J Cardiothorac Surg; 2017 Mar; 51(3):587-590. PubMed ID: 28082469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shear-stress induced acquired von Willebrand syndrome in children with congenital heart disease.
    Loeffelbein F; Funk D; Nakamura L; Zieger B; Grohmann J; Siepe M; Kroll J; Stiller B
    Interact Cardiovasc Thorac Surg; 2014 Dec; 19(6):926-32. PubMed ID: 25228244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of an automated chemiluminescent assay to a manual ELISA assay for determination of von Willebrand Factor collagen binding activity on VWD plasma patients previously diagnosed through molecular analysis of VWF.
    Jousselme E; Jourdy Y; Rugeri L; Négrier C; Nougier C
    Int J Lab Hematol; 2018 Feb; 40(1):77-83. PubMed ID: 28980759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays.
    Favaloro EJ; Mohammed S
    Thromb Res; 2014 Dec; 134(6):1292-300. PubMed ID: 25300811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
    Favaloro EJ; Thom J; Patterson D; Just S; Baccala M; Dixon T; Meiring M; Koutts J; Rowell J; Baker R
    Blood Coagul Fibrinolysis; 2009 Sep; 20(6):475-83. PubMed ID: 19584715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idiopathic pulmonary arterial hypertension - a unrecognized cause of high-shear high-flow haemostatic defects (otherwise referred to as acquired von Willebrand syndrome) in children.
    Pelland-Marcotte MC; Humpl T; James PD; Rand ML; Bouskill V; Reyes JT; Bowman ML; Carcao MD
    Br J Haematol; 2018 Oct; 183(2):267-275. PubMed ID: 30141279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
    Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
    Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB).
    Favaloro EJ; Mohammed S
    Methods Mol Biol; 2017; 1646():417-433. PubMed ID: 28804845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of the collagen binding activity (VWF:CB) in the range of tests for the diagnosis and classification of von Willebrand disease.
    Ferhat-Hamida MY; Boukerb H; Hariti G
    Ann Biol Clin (Paris); 2015; 73(4):461-8. PubMed ID: 26411913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.